Interactions between Seripalase (BRINEURA) and other drugs and description of risks of combined use

Seripase (BRINEURA, cerliponase alfa) is a recombinant human cerebrospinal fluid exocrine enzyme used to treat CLN2 neurodegenerative diseases. It slows down neurodegenerative processes by replacing missing lysosomal enzymes and degrading abnormal accumulation of polymers in cerebrospinal fluid. Because it is an enzyme preparation and is mainly administered via intracerebroventricular injection, the concentration of the drug in the blood system is limited, but potential drug interactions still need to be noted.

Seripalase may cause an immune reaction or infusion-related allergic reaction. When coadministering corticosteroids, antihistamines or other immunosuppressants, attention should be paid to changes in the suppressed or activated state of the immune system. Immunosuppressive drugs may reduce the risk of enzyme-induced immune responses, but excessive suppression may increase the risk of infection. Combination medication should be carried out under strict supervision by doctors, and the dosage and infusion regimen should be adjusted to ensure safety.

When treatingCLN2 patients, patients are often treated with anti-epileptic drugs, sedatives, or spasticity-controlling drugs. Currently, seripalase has not shown significant metabolic interactions with these drugs. However, if the patient experiences sedation or blood pressure changes during infusion, attention should be paid to the cumulative effects or synergistic side effects of the drugs to prevent respiratory depression or disturbance of consciousness. Continuous clinical monitoring should be maintained, especially during initial combined use.

Major risks when seripase is used in combination with other drugs include enhanced allergic reactions, exacerbation of infusion-related side effects, and immune system interference. To reduce the risk, it is recommended: 1) Strictly follow the pre-infusion pretreatment regimen, such as using antihistamines or short-course glucocorticoids; 2) Closely monitor patients in medical institutions when the combination is used for the first time Monitor vital signs; 3) Avoid concurrent use with drugs that may increase thrombosis, cardiovascular burden, or respiratory depression; 4) Regularly assess the patient's immune status and neurological response. Through scientific management, the risks of combined medication can be minimized while ensuring efficacy.

Reference materials:https://www.drugs.com/